Holen Sie sich die Stockscreener-App
3.01
3.08%
0.09
Vorhandelsmarkt:
2.95
-0.06
-1.99%
Schlusskurs vom Vortag:
$2.92
Offen:
$2.95
24-Stunden-Volumen:
214.73K
Relative Volume:
0.77
Marktkapitalisierung:
$83.81M
Einnahmen:
$875.70K
Nettoeinkommen (Verlust:
$-39.57M
KGV:
-2.2424
EPS:
-1.3423
Netto-Cashflow:
$-33.65M
1W Leistung:
+5.99%
1M Leistung:
+20.40%
6M Leistung:
-17.76%
1J Leistung:
-34.85%
1-Tages-Spanne:
$2.90
$3.05
1-Wochen-Bereich:
$2.83
$3.10
52-Wochen-Spanne:
$2.22
$5.74
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Firmenname
Vistagen Therapeutics Inc
Sektor
Branche
Telefon
650-577-3600
Adresse
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Vergleichen Sie VTGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
3.01 | 83.81M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-07 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-07 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-07-22 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-02-18 | Eingeleitet | Jefferies | Buy |
| 2021-01-04 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | Eingeleitet | Maxim Group | Buy |
| 2018-02-08 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-03-28 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Vistagen Therapeutics Inc Aktie (VTGN) Neueste Nachrichten
Head to Head Survey: Aquestive Therapeutics (NASDAQ:AQST) & Vistagen Therapeutics (NASDAQ:VTGN) - Defense World
Jane Street Group LLC Purchases Shares of 19,659 Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World
Vistagen reports positive outcomes from Phase IIA cancer cachexia trial - Yahoo Finance
Vistagen reports promising PH284 nasal spray study By Investing.com - Investing.com Canada
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia - sharewise
Vistagen reports promising PH284 nasal spray study - Investing.com
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Geode Capital Management LLC - Defense World
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder - sharewise
HighTower Advisors LLC Purchases New Holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World
VTGN stock touches 52-week low at $2.38 amid market challenges - Investing.com India
VTGN stock touches 52-week low at $2.38 amid market challenges By Investing.com - Investing.com South Africa
Mental Disorder Treatment Market Innovations and Key Players: - openPR
PD-LID Market Growth to Accelerate in Forecast Period - openPR
VTGN Stock Touches 52-Week Low at $2.47 Amid Market Challenges By Investing.com - Investing.com South Africa
VTGN Stock Touches 52-Week Low at $2.47 Amid Market Challenges - Investing.com
VTGN (Vistagen Therapeutics) Inventory Turnover : 0.00 (As of Sep. 2024) - GuruFocus.com
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Great Point Partners LLC - MarketBeat
Analyzing Vistagen Therapeutics (NASDAQ:VTGN) and Daré Bioscience (NASDAQ:DARE) - Defense World
VTGN Stock Touches 52-Week Low at $2.51 Amid Market Challenges - Investing.com India
Anxiety drug trials keep Stifel optimistic on VistaGen stock's upside potential - Investing.com Canada
Reviewing Vistagen Therapeutics (NASDAQ:VTGN) and Minerva Neurosciences (NASDAQ:NERV) - Defense World
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Down 18.1% in October - Defense World
Great Point Partners LLC Increases Stake in Vistagen Therapeutics Inc - GuruFocus.com
Citadel Advisors LLC Increases Stake in Vistagen Therapeutics Inc - GuruFocus.com
We're Hopeful That Vistagen Therapeutics (NASDAQ:VTGN) Will Use Its Cash Wisely - Simply Wall St
Vistagen Therapeutics adds SKDK, GCI Health alum Michelle Peters Wellington - MM+M Online
Vistagen CEO to Present at Stifel 2024 Healthcare Conference | VTGN Stock News - StockTitan
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2025 Earnings Call Transcript - Insider Monkey
Q1 Earnings Estimate for VTGN Issued By William Blair - MarketBeat
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates - MSN
Vistagen Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 - Marketscreener.com
Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlight - GuruFocus.com
Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ... - Yahoo Finance
Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ... By GuruFocus - Investing.com Canada
Vistagen Therapeutics Reports Increased R&D Expenses - TipRanks
Vistagen Therapeutics Inc Reports Q2 2025 Revenue of $183,000, M - GuruFocus.com
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update - Business Wire
Vistagen reports Q2 EPS (42c), consensus (39c) - TipRanks
Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Report Preview: What to Expect - GuruFocus.com
Vistagen to Present at the 2024 Neuroscience Education Institute Congress - Business Wire
Vistagen Therapeutics (VTGN) Scheduled to Post Earnings on Thursday - MarketBeat
Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024 - sharewise
VTGN (Vistagen Therapeutics) Profitability Rank : 1 (As of Jun. 2024) - GuruFocus.com
Generalized Anxiety Disorder Pipeline 2024: Clinical Trials - openPR
Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder - Seeking Alpha
VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know - MSN
Finanzdaten der Vistagen Therapeutics Inc-Aktie (VTGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):